Novo’s Ozempic Patent Expires Jan. 4 in Canada, But Generics Aren’t Imminent
Plus: The economy is on thin ice
Welcome back to Canada Daily, the newsletter on business, economics and politics from Vancouver to Montreal and beyond. If this was forwarded to you, sign up here. Programming note: This newsletter will take a break for the holidays and return on Jan. 2.
Ozempic, Novo Nordisk’s diabetes drug, is so popular that the brand name now functions as a generic term for a growing array of semaglutides and other weight-loss drugs.